Isis Pharmaceuticals, Inc. (ISIS) is a drug discovery and development company focused on the therapeutic target RNA and developing products from RNA-based technologies, such as 'antisense.' We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases.
The company's leading candidates are mipomersen for high cholesterol and ISIS-113715 for diabetes, along with several other proprietary and partnered programs for oncology, inflammatory disease, asthma, and viral infections. Our financial model forecasts sustained profitability in 2011.
We are reiterating or rating on Isis Pharmaceuticals of a Buy and maintaining our price target of $22.
Read the full analyst report on ISIS
Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all todays Analyst Blog entries on Zacks.com.